Triple-negative breast cancer (TNBC) is a highly metastatic and heterogeneous type of tumor, representing 15% of breast cancer cases. To tackle the drug-resistant phenotype of TNBC, effective targeted combinatorial approaches are urgently needed. Writing in EMBO Molecular Medicine journal, researchers from the Centre for Genomic Regulation and collaborators demonstrate that the simultaneous inhibition of lysyl oxidase-like 2 (LOXL2) and bromodomain-containing protein 4 (BRD4) synergistically limits TNBC proliferation in vitro and in vivo.